SCHEMBL6217364

SCHEMBL6217364

COC(=O)c1ccc2[nH]c(S)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 3/20 0.50
HTT P42858 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
RHEB Q15382 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 2/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
CREBBP Q92793 1/20 0.48
HSD17B10 Q99714 1/20 0.47
PSMB8 P28062 1/20 0.47
KIF11 P52732 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6217370 0.88 HTT (0.64) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL24430177 0.86 RAB9A (0.56) ALDH1A1HTTSMN1; SMN2NPC1RAB9A
SCHEMBL1170648 0.84 KDM4E (0.61) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL7795891 0.84 HCRTR1 (0.53) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL16182400 0.84 L3MBTL1 (0.38) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL5032566 0.83 HSP90AA1 (0.53) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL2098919 0.83 KDM4E (0.51) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL13080216 0.83 KIF11 (0.42) KDM4EALDH1A1NPC1RAB9AHPGD
SCHEMBL18782890 0.82 KDM4E (0.50) KDM4EALDH1A1LMNAHTTL3MBTL1
SCHEMBL1202574 0.82 KDM4E (0.50) KDM4EALDH1A1LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050148634-A1 1-N-Aminobenzimidazole derivatives ZERIA PHARMACEUTICAL CO., LTD (JP) 2005-07-07 US claimed
US-20050148634-A1 1-N-Aminobenzimidazole derivatives ZERIA PHARMACEUTICAL CO., LTD (JP) 2005-07-07 US disclosed
EP-1020451-B1 ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2005-06-15 EP disclosed
US-6797717-B2 ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS KOWA COMPANY, LTD. (JP) 2004-09-28 US disclosed
US-20030087928-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD., JAPAN 2003-05-08 US disclosed
US-20020099074-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD.,JAPAN 2002-07-25 US disclosed
US-6362208-B1 ANTICHOLESTEROL AGENT KOWA COMPANY, LTD. (JP) 2002-03-26 US disclosed
EP-1020451-A1 NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-07-19 EP disclosed
US-5616581-A BACTERICIDES YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-04-01 US disclosed
EP-0457331-B1 Piperidine derivatives and antiulcer composition containing the same MEIJI SEIKA KAISHA (JP) 1996-11-20 EP disclosed
US-5504082-A BACTERICIDE FOR HELICOBACTER, ANTIULCER AGENT, GASTRIC ACIDSUPPRESSOR YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1996-04-02 US disclosed
EP-0644191-A1 PYRIDINE COMPOUND AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-03-22 EP disclosed
EP-0129409-B1 Thiazolo - and thiazinobenzimidazoles WYETH JOHN & BROTHER LTD (GB) 1993-10-27 EP disclosed
US-5185347-A PIPERIDINE COMPOUNDS AND ANTIULCER COMPOSITION CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 1993-02-09 US disclosed
EP-0457331-A1 Piperidine derivatives and antiulcer composition containing the same MEIJI SEIKA KAISHA LTD. (JP) 1991-11-21 EP disclosed
US-4873237-A ANTIULCER AGENTS JOHN WYETH & BROTHER LIMITED (GB) 1989-10-10 US disclosed
EP-0129409-A2 Thiazolo - and thiazinobenzimidazoles JOHN WYETH & BROTHER LIMITED (GB) 1984-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087928-A1 Novel anilide compounds and drugs containing the same ACAT1, ACAT2, LCAT KDM4E 450/4885ALDH1A1 211/4885LMNA 4625/4885
US-20050148634-A1 1-N-Aminobenzimidazole derivatives CYP1B1, CYP2E1, CYP1A1 KDM4E 2128/4885ALDH1A1 57/4885LMNA 3866/4885
US-20020099074-A1 Novel anilide compounds and drugs containing the same SOAT1, SOAT2, LCAT KDM4E 579/4885ALDH1A1 236/4885LMNA 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.